Abstract: A composition including modified macrophages and its use in the treatment of melanoma and pancreatic cancer. The modified macrophages have a deletion of fragile-site associated tumor suppressor (FATS) or include a small interfering RNA (siRNA) capable of silencing the FATS. The knockout or inhibition of FATS may promote the polarization of MO macrophages into M1 macrophages and suppress the polarization of MO macrophages into M2 macrophages. The FATS can be used as a target for the production of medications for the treatment of cancer or tumors.

Abstract: Disclosed are a use of FATS gene, by knocking out or inhibiting the FATS gene, in promoting macrophage polarization into M1 type and/or inhibiting macrophage polarization into M2 type, or activating and proliferating killer T cells; and a use of FATS gene or an expression product thereof in any one of i) developing and screening a functional product for tumors and ii) preparing a functional product for treatment or prevention of tumors. The present application demonstrates that FATS gene or an expression product thereof is closely related to tumors, and thus can be used as a drug target to develop tumor-related drugs. Cellular and molecular mechanisms of the FATS gene or its expression product in tumors are further demonstrated, providing an effective targeting means or a major basis for the development of tumor-related drugs.